Sheldon L. Koenig - Mar 14, 2022 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
President and CEO, Director
Signature
/s/ Richard B. Bartram, by power of attorney
Stock symbol
ESPR
Transactions as of
Mar 14, 2022
Transactions value $
$0
Form type
4
Date filed
3/16/2022, 05:08 PM
Previous filing
Nov 1, 2021
Next filing
Mar 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ESPR Common Stock Award $0 +116K +146.3% $0.00 195K Mar 14, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ESPR Stock Option (right to buy 492K Mar 14, 2022 Common Stock 492K $4.74 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The awards will vest quarterly over four years beginning on March 15, 2022.
F2 Consists of 195,288 shares of common stock held, including 2,588 shares acquired in Esperion's Employee Stock Purchase Plan.